It has been 10 trading days since the opening of the Beijing stock exchange. Among the first 81 listed companies, there are 12 in Jiangsu, ranking first in China. What are the characteristics of these 12 companies?
China Securities Journal · China Securities Taurus reporter found that many of them are quite attractive, and Shanghai and Shenzhen listed companies and industrial capital “appear” in the shareholder seats of many companies.
In an interview with China Securities Journal · China Securities Taurus reporter, Jiangsu securities regulatory bureau said that in the next step, Jiangsu securities regulatory bureau will promote the growth of listed companies not only in “quantity”, but also in “quality”, support the vigorous development of small and medium-sized enterprises, and strive to be an example, model and take the lead in promoting high-quality development, preventing and resolving financial risks.
“Shanghai and Shenzhen companies + industrial capital” work together to help
The data show that the above 12 companies are involved in 8 Shenwan industries, with the largest number in the pharmaceutical, biological and mechanical equipment industries, including Deyuan medicine and Lude medical; There are two companies in the automotive industry.
Due to the fit of industrial chain and business coordination, many listed companies in Shanghai and Shenzhen invest in their favorite targets as strategic investors in order to become long-term strategic partners.
In response to investors’ questions last month, Shanghai company Sobute New Materials Co.Ltd(603916) in the concrete admixture industry said, “it has a cooperative relationship with Xujie technology in business and is a long-term strategic partner.”
According to the latest shareholder list of Xujie technology, Sobute New Materials Co.Ltd(603916) holds 1748000 shares, which is the top ten new shareholders in this year’s semi annual report. According to Sobute New Materials Co.Ltd(603916) in Jiangsu Province, Xujie technology is an integrated solution supplier in the field of prefabricated construction. With the continuous improvement of China State Construction Engineering Corporation Limited(601668) assembly rate, Xujie technology, relying on its own R & D strength and design and construction team, ushers in more market opportunities in the prefabricated construction market in the Yangtze River Delta and even the whole country. “This investment not only focuses on the development prospect of the enterprise, but also selects a good cooperation field. We will cooperate for a long time and jointly expand the market share.”
The preference of China Nuclear Industry Group’s Shenzhen main board company Sufa Technology Industry Co.Ltd.Cnnc(000777) for Changfu shares can be seen from its nearly 9% stake in the latter.
According to public data, Changfu Co., Ltd. specializes in the R & D, production and sales of valve actuators. It has earlier set foot in the field of civil nuclear power in the industry. It is one of the first enterprises to obtain the design and manufacturing license of civil nuclear safety equipment in the industry. According to the data, in the 2017 annual report, Sufa Technology Industry Co.Ltd.Cnnc(000777) has entered the list of its top ten shareholders.
In addition, yunchuang data processed by Shengeng big data is “equity bound” with Shenzhen company Tongding Interconnection Information Co.Ltd(002491) . According to the investigation, in June 2015, Tongding Interconnection Information Co.Ltd(002491) invested in yunchuang data. At present, the shareholding ratio is 13.72%, which is the second largest single shareholder of the company. Moreover, Ningbo paradise Silicon Valley Xinfeng equity investment partnership (limited partnership) invested in yunchuang data in August 2017. At that time, it exclusively subscribed for more than 2 million additional shares of yunchuang data, with a current shareholding ratio of 4.81%.
It is worth mentioning that Hechang polymerization, a modified plastic enterprise registered in Suzhou, Jiangsu Province, is not only favored by local industrial capital, but also favored by Beijing state-owned assets.
As of September 30 this year, among the top ten circulating shareholders of Hechang aggregation, Shanghai Qianyi venture capital partnership (limited partnership) and Shanghai Tianshi new equity investment center (limited partnership), the former accounted for 5.51% and 3.67% of the circulating shares respectively.
Tianyancha shows that in addition to investing in Hechang polymerization, Shanghai Qianyi also holds Anhui Landun Photoelectron Co.Ltd(300862) 2535800 shares of GEM companies and Shanghai Taihe Water Environmental Technology Development Co.Ltd(605081) 1303800 shares of Shanghai main board companies. In terms of ownership structure, Qin Daqian has the largest single shareholding in Shanghai Qianyi, reaching 39.06%. According to public information, Qin Daqian is the chairman of Jiangsu Huafang group. In addition, tracing back to the shareholders behind Shanghai Tianshi new, Beijing State-owned Assets Management Co., Ltd. appeared.
existing companies have implemented equity incentive
The accumulation of core talents for future development or the realization of technological breakthroughs in key projects are inseparable from the link of effective incentive and the guarantee of system and mechanism. How to “take root” for the long-term development of the company? The role of equity incentive is becoming prominent.
The data show that since 2018, some of the Jiangsu companies that have landed on the Beijing stock exchange have implemented equity incentive.
Specifically, at the end of May this year, Deyuan pharmaceutical disclosed the restricted stock incentive plan (Draft) for 2021. The company plans to grant 2.828 million restricted shares to the financial director, two senior executives of the general manager and 128 core employees, accounting for 4.53% of the total share capital of the company at the time of the announcement, and the proportion granted to incentive objects for the first time is 100%. The initial grant price of restricted shares is 11.02 yuan per share.
It is worth mentioning that the assessment management measures of Deyuan pharmaceutical set both revenue indicators and non net profit deduction indicators at the company level, and set assessment requirements at the individual level.
A few weeks after the disclosure of the incentive plan, the company announced the grant of restricted shares, of which the grant date was June 22, 2021 and the registration date was July 27, 2021, and the grant price was 10.75 yuan / share after dividend adjustment.
The equity incentive plan of Changfu shares was disclosed earlier and the relevant draft was announced in early 2018. The plan is the first equity incentive plan of the company, involving a total of 16 incentive objects and 440000 incentive shares. The incentive shares come from the partnership shares of Changzhou Shuangling enterprise management consulting partnership (limited partnership), a shareholding platform. This share incentive is implemented to the incentive objects in the form of the transfer of partnership shares in the same proportion by the existing 23 partners of the shareholding platform. The incentive plan was implemented on March 31, 2018.
Some market participants believe that equity incentive has been gradually normalized in Shanghai and Shenzhen listed companies, and most of the companies landing on the Beijing stock exchange are still in the early stage of development. They need to determine relevant incentive indicators according to their own business conditions. They can try small-scale incentive, group incentive and continuous incentive, and explore incentive schemes in line with the law of the company’s development with the support of relevant policies.
(China Securities Journal)
